Specialty care platform Lantern has partnered with Pelago, a digital substance use management platform, to offer personalized substance use disorder (SUD) treatment to Lantern’s clients. Starting in 2025, Lantern clients will have access to Pelago's SUD treatments through the company's platform, which covers all substances and severities, including tobacco, cannabis, alcohol, and opioid use disorders. Pelago will also provide telemedicine services alongside in-person treatment options.
Pelago’s approach tailors care based on individual health, habits, genetics, and goals, offering support for members at any stage of the substance use spectrum. Pelago President Frank Jennings highlighted that this partnership represents a major step in delivering high-quality care solutions for employers and their members. By combining Pelago’s expertise in substance use management with Lantern’s Center of Excellence and specialty care, they aim to set a new standard for addressing complex healthcare challenges.
Lantern President Dickon Waterfield emphasized the company's focus on connecting the workforce to top-tier specialty care, particularly in substance use treatment, where many individuals face barriers to effective and affordable options. Through Pelago, Lantern clients will soon access science-backed, tailored SUD programs both in-person and via telehealth, designed to improve health outcomes.
This collaboration follows Lantern’s recent efforts to expand its services, including a partnership with the Global Appropriateness Measures (GAM) physician consortium to enhance its Network of Excellence. Lantern also teamed up with the 32BJ Health Fund in 2024 to offer comprehensive benefits and access to high-quality surgeons and specialists starting in January 2025.
Meanwhile, Pelago has been expanding its own offerings, launching an inpatient Centers of Excellence network to improve care access and treatment completion. Pelago also secured $58 million in Series C funding, bringing its total raise to $151 million, with investment from Atomico, Y Combinator, Octopus Ventures, Kinnevik AB, Eight Roads, and GreyMatter Capital.
Click here to read the original news story.